Compare IDA & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDA | BLCO |
|---|---|---|
| Founded | 1915 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Ophthalmic Goods |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 6.0B |
| IPO Year | 1998 | 2022 |
| Metric | IDA | BLCO |
|---|---|---|
| Price | $141.92 | $16.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $139.57 | $18.55 |
| AVG Volume (30 Days) | 403.1K | ★ 444.0K |
| Earning Date | 05-22-2026 | 05-21-2026 |
| Dividend Yield | ★ 2.50% | N/A |
| EPS Growth | ★ 7.27 | N/A |
| EPS | ★ 5.90 | N/A |
| Revenue | $1,746,972,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $10.87 | $8.61 |
| Revenue Next Year | $12.99 | $5.52 |
| P/E Ratio | $23.91 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $109.30 | $10.45 |
| 52 Week High | $145.94 | $18.92 |
| Indicator | IDA | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 34.79 |
| Support Level | $138.41 | $14.39 |
| Resistance Level | $145.37 | $17.44 |
| Average True Range (ATR) | 2.58 | 0.52 |
| MACD | -0.62 | -0.21 |
| Stochastic Oscillator | 45.67 | 3.47 |
Idacorp Inc is a holding company that, through its subsidiaries, acts as an electric utility engaged in the generation, transmission, distribution, sale, and purchase of electric energy and capacity. The company's only reportable segment is utility operations. The utility operations segment's primary source of revenue is the regulated operations of Idaho Power. The company serves commercial and industrial customers, which are involved in food processing, electronics and general manufacturing, agriculture, health care, government, education, and information technology.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.